 An initial subset of 10 subjects will be enrolled in the study will be limited to only those patients 12 years of age or older and to those who have mild to moderate Crohns Disease and randomized to receive FMT or placebo. Wed expect short term adverse events to occur within 7 days of FMT administration. Individual subject safety data will be reviewed by the PIto assess whether FMT appears to be safe in the subject before continuing the subject towards open-label use of FMT. 